Zacks: Analysts Anticipate Ionis Pharmaceuticals Inc (NASDAQ:IONS) Will Post Quarterly Sales of $407.23 Million

Equities research analysts forecast that Ionis Pharmaceuticals Inc (NASDAQ:IONS) will announce $407.23 million in sales for the current quarter, according to Zacks Investment Research. Six analysts have issued estimates for Ionis Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $384.20 million and the highest estimate coming in at $427.73 million. Ionis Pharmaceuticals posted sales of $192.11 million during the same quarter last year, which indicates a positive year over year growth rate of 112%. The firm is expected to issue its next earnings results on Wednesday, February 26th.

On average, analysts expect that Ionis Pharmaceuticals will report full year sales of $1.04 billion for the current fiscal year, with estimates ranging from $1.01 billion to $1.06 billion. For the next fiscal year, analysts forecast that the firm will post sales of $797.61 million, with estimates ranging from $647.21 million to $870.00 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Ionis Pharmaceuticals.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported $0.18 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.49. The company had revenue of $168.00 million for the quarter, compared to analyst estimates of $152.47 million. Ionis Pharmaceuticals had a net margin of 52.26% and a return on equity of 36.31%. The company’s revenue was up 15.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.03) earnings per share.

Several research firms recently commented on IONS. Sanford C. Bernstein upgraded shares of Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $80.00 price target on the stock in a research note on Tuesday, September 10th. William Blair began coverage on shares of Ionis Pharmaceuticals in a research note on Thursday, November 14th. They issued a “market perform” rating on the stock. Oppenheimer began coverage on shares of Ionis Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $77.00 price target on the stock. Cantor Fitzgerald set a $65.00 price target on shares of Ionis Pharmaceuticals and gave the company a “hold” rating in a research note on Tuesday, October 15th. Finally, Cowen restated a “hold” rating on shares of Ionis Pharmaceuticals in a research note on Thursday, November 7th. Eight research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $75.67.

In other Ionis Pharmaceuticals news, SVP Richard S. Geary sold 10,000 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $64.61, for a total transaction of $646,100.00. Also, Director Joseph Klein III sold 812 shares of the stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $62.90, for a total transaction of $51,074.80. Following the sale, the director now owns 12,683 shares in the company, valued at $797,760.70. The disclosure for this sale can be found here. Insiders have sold 38,154 shares of company stock worth $2,397,122 over the last quarter. Corporate insiders own 2.40% of the company’s stock.

A number of institutional investors have recently made changes to their positions in IONS. CWM LLC boosted its stake in shares of Ionis Pharmaceuticals by 361.4% in the 2nd quarter. CWM LLC now owns 406 shares of the company’s stock valued at $26,000 after purchasing an additional 318 shares in the last quarter. Quest Capital Management Inc. ADV acquired a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter valued at approximately $36,000. Rehmann Capital Advisory Group boosted its stake in shares of Ionis Pharmaceuticals by 41.3% in the 2nd quarter. Rehmann Capital Advisory Group now owns 592 shares of the company’s stock valued at $38,000 after purchasing an additional 173 shares in the last quarter. Venturi Wealth Management LLC acquired a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter valued at approximately $40,000. Finally, Bradley Foster & Sargent Inc. CT acquired a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter valued at approximately $49,000. Hedge funds and other institutional investors own 85.65% of the company’s stock.

IONS stock opened at $63.05 on Wednesday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 10.31 and a current ratio of 10.39. The company’s 50-day simple moving average is $59.55 and its 200 day simple moving average is $62.84. Ionis Pharmaceuticals has a 52 week low of $48.27 and a 52 week high of $86.58. The company has a market capitalization of $8.68 billion, a PE ratio of 17.58, a price-to-earnings-growth ratio of 2.22 and a beta of 1.91.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Featured Story: Technical Analysis

Get a free copy of the Zacks research report on Ionis Pharmaceuticals (IONS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.